Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation

Summary

It was the aim of the present study to investigate factor II levels in liver cirrhosis (LC) patients with portal vein thrombosis (PVT) carrying the heterozygous G20210A prothrombin (PT) mutation. Plasma concentrations of factor II, VII, X, V, protein C (PC) total protein S (tPS) antithrombin (AT) and D-dimers (DD) were measured in 13 LC patients with PVT heterozygous for PT G20210A, in 13 LC patients with PVT without PT G20210A and in 13 LC controls matched by age, sex and Child-Pugh score. Crude factor II and factor II/DD ratio were highest in LC patients with PVT heterozygous for PT G20210A (p=0.03 and p=0.02 respectively). The factor II/PC ratio, expression of a procoagulant/anticoagulant imbalance was highest in the same group (p=0.0008). Plasma factor II levels are elevated in LC patients heterozygous for PT G20210A and may favour PVT.

Keywords

Liver cirrhosis - portal vein thrombosis - prothrombin

• References

• 1 Amitrano L. et al. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22: 83-96.
• 2 Amitrano L. et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345-8.
• 3 Amitrano L. et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736-41.
• 4 Colucci M. et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFI-mediated mechanism. Blood 2004; 103: 2157-61.
• 5 Pugh RN. et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
• 6 Poort SR. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
• 7 Margaglione M. et al. Raised plasma fibrinogen concentrations in subjects attending a metabolic wardrelation to family history and vascular risk factors. Thromb Haemost 1995; 73: 579-83.
• 8 Margaglione M. et al. Detection of the factor V Leiden using SSCP. Thromb Haemost 1996; 76: 814-5.
• 9 Corral J. et al. Clinical and analytical relevance of the combination of the prothrombin 20210G/A and factor V Leiden: results from a large family. Br J Haematol 1999; 1054: 560-3.
• 10 Cattaneo M. et al. The G20210A mutation of the prothrombin gene in patients with previous first episode of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolare reductase C677T and plasma prothrombin levels. Thromb Res 1999; 93: 1-8.
• 11 Franco RF. et al. The 20210 G_A mutation in the 3– untranslated region of the protrombin gene and the risk of arterial thrombotic disease. Br J Haematol 1999; 104: 50-4.
• 12 Hillarp A. et al. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78: 990-2.
• 13 Gouin-Thibault I. et al. Markers of activated coagulation in patients with factor V Leiden and/or G20210A prothrombin gene mutation. Thromb Res 2002; 107: 7-11.
• 14 Colucci M. et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003; 38: 230-7.
• 15 Tripodi A. et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41: 553-8.
• 16 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. NEJM 2001; 344: 1222-31.
• 17 Erkan O. et al. Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. Eur J Gastroenterol Hepatol 2005; 17: 339-43.